GPP 78 hydrochloride
Inhibitor of nicotinamide phosphoribosyltransferase (NAMPT); potently depletes NAD levels and exhibits cytotoxicity in vitro (IC50 values are 3.0 and 3.8 nM respectively). Also shown to induce autophagy in neuroblastoma cells.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 476.01. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.1 mL||10.5 mL||21.01 mL|
|5 mM||0.42 mL||2.1 mL||4.2 mL|
|10 mM||0.21 mL||1.05 mL||2.1 mL|
|50 mM||0.04 mL||0.21 mL||0.42 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Colombano et al (2010) A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J.Med.Chem. 53 616 PMID: 19961183
If you know of a relevant reference for GPP 78 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: GPP78 hydrochloride NMPRTase NAMPT NAD nicotinamide phosphoribosyltransferase inhibitors inhibits autophagy induces inducers NAMPT
Citations for GPP 78 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for GPP 78 hydrochloride. Do you know of a great paper that uses GPP 78 hydrochloride from Tocris? If so please let us know.
Literature in this Area
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.